Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$49.25
-0.8%
$45.75
$16.91
$53.62
$834.64M1.51220,615 shs249,796 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$11.63
+0.7%
$12.66
$3.91
$14.91
$801.62M1.951.42 million shs1.39 million shs
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
$2.28
-10.2%
$1.41
$0.61
$5.77
$461.69M2.8919.12 million shs20.83 million shs
10x Genomics stock logo
TXG
10x Genomics
$11.83
-4.4%
$12.87
$6.78
$18.21
$1.47B2.052.61 million shs2.23 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
0.00%+7.28%+3.01%+23.68%+157.99%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%-14.30%-15.48%+11.61%+3.10%
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
0.00%+36.94%+49.02%+29.55%+179.27%
10x Genomics stock logo
TXG
10x Genomics
0.00%+3.14%-10.85%-2.63%-24.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$49.25
-0.8%
$45.75
$16.91
$53.62
$834.64M1.51220,615 shs249,796 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$11.63
+0.7%
$12.66
$3.91
$14.91
$801.62M1.951.42 million shs1.39 million shs
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
$2.28
-10.2%
$1.41
$0.61
$5.77
$461.69M2.8919.12 million shs20.83 million shs
10x Genomics stock logo
TXG
10x Genomics
$11.83
-4.4%
$12.87
$6.78
$18.21
$1.47B2.052.61 million shs2.23 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
0.00%+7.28%+3.01%+23.68%+157.99%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%-14.30%-15.48%+11.61%+3.10%
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
0.00%+36.94%+49.02%+29.55%+179.27%
10x Genomics stock logo
TXG
10x Genomics
0.00%+3.14%-10.85%-2.63%-24.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allient Inc. stock logo
ALNT
Allient
2.00
Hold$35.00-28.93% Downside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.71
Moderate Buy$28.33143.62% Upside
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
2.25
Hold$3.4852.41% Upside
10x Genomics stock logo
TXG
10x Genomics
2.38
Hold$13.6515.42% Upside

Current Analyst Ratings Breakdown

Latest QSI, TXG, EYPT, and ALNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/9/2025
10x Genomics stock logo
TXG
10x Genomics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/8/2025
Allient Inc. stock logo
ALNT
Allient
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Allient Inc. stock logo
ALNT
Allient
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/13/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/11/2025
10x Genomics stock logo
TXG
10x Genomics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$15.00
(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allient Inc. stock logo
ALNT
Allient
$529.97M1.58$3.03 per share16.23$15.72 per share3.13
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M18.53N/AN/A$4.93 per share2.36
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
$3.06M150.87N/AN/A$1.29 per share1.77
10x Genomics stock logo
TXG
10x Genomics
$610.78M2.41N/AN/A$5.81 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allient Inc. stock logo
ALNT
Allient
$13.17M$0.8657.2726.91N/A2.75%9.97%4.67%11/5/2025 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.68N/AN/AN/A-337.93%-63.80%-50.72%11/6/2025 (Estimated)
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
-$101.01M-$0.68N/AN/AN/A-3,120.14%-44.57%-39.45%11/5/2025 (Confirmed)
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)

Latest QSI, TXG, EYPT, and ALNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.77N/AN/AN/A$3.33 millionN/A
11/6/2025Q3 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.27N/AN/AN/A$142.50 millionN/A
11/5/2025Q3 2025
Allient Inc. stock logo
ALNT
Allient
$0.48N/AN/AN/A$133.28 millionN/A
11/5/2025Q3 2025
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
-$0.17N/AN/AN/A$0.60 millionN/A
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million
8/6/2025Q2 2025
Allient Inc. stock logo
ALNT
Allient
$0.48$0.57+$0.09$0.34$132.89 million$139.58 million
8/6/2025Q2 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.67-$0.85-$0.18-$0.85$6.82 million$5.33 million
8/5/2025Q2 2025
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
-$0.16-$0.16N/A-$0.16$1.28 million$0.59 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allient Inc. stock logo
ALNT
Allient
$0.120.24%N/A13.95%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest QSI, TXG, EYPT, and ALNT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Allient Inc. stock logo
ALNT
Allient
quarterly$0.030.3%8/21/20258/21/20259/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allient Inc. stock logo
ALNT
Allient
0.70
3.74
2.17
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
8.00
7.91
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
N/A
9.43
9.27
10x Genomics stock logo
TXG
10x Genomics
N/A
5.84
5.23

Institutional Ownership

CompanyInstitutional Ownership
Allient Inc. stock logo
ALNT
Allient
61.57%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
39.90%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Allient Inc. stock logo
ALNT
Allient
15.60%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
30.04%
10x Genomics stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allient Inc. stock logo
ALNT
Allient
2,52516.95 million14.30 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.93 million65.85 millionOptionable
Quantum-Si Incorporated stock logo
QSI
Quantum-Si
150202.49 million141.67 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240124.49 million112.80 millionOptionable

Recent News About These Companies

10x Genomics (NASDAQ:TXG) Stock Price Up 6.2% - Still a Buy?
Q3 EPS Estimates for 10x Genomics Increased by Analyst
Why 10x Genomics (TXG) Stock Is Trading Up Today
Weiss Ratings Reaffirms "Sell (D-)" Rating for 10x Genomics (NASDAQ:TXG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allient stock logo

Allient NASDAQ:ALNT

$49.25 -0.38 (-0.77%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$49.30 +0.05 (+0.10%)
As of 10/17/2025 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$11.63 +0.08 (+0.69%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$11.44 -0.19 (-1.63%)
As of 10/17/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quantum-Si stock logo

Quantum-Si NASDAQ:QSI

$2.28 -0.26 (-10.24%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$2.32 +0.04 (+1.54%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$11.83 -0.55 (-4.44%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$11.91 +0.08 (+0.67%)
As of 10/17/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.